Tianjin Ringpu Bio-technology Co., Ltd. Class A

Tianjin Ringpu Bio-technology Co., Ltd. Class A

SSZSE:300119
16.54
CNY
-0.07
(-0.42%)
0.85EPS
22.57P/E
7.79BMarket Cap
Mar 29Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.94
1.52
2.04
2.46
2.59
2.94
3.69
5.05
4.99
4.5
5.84
6.67
7.48
7.77
Basic EPS, GAAP
0.39
0.07
0.28
0.34
0.26
0.29
0.49
1.01
1.03
0.75
0.98
0.65
0.88
0.74
Free Cash Flow per Basic Share
-0.42
-0.14
0.19
0.2
- -
0.15
0.39
0.33
0.19
0.04
0.34
1.2
0.27
- -
Dividend per Share
0.13
0.11
0.11
0.18
0.19
0.2
0.22
0.29
0.45
0.41
0.35
0.47
0.37
0.47
Book Value per Share
4.17
4.16
4.13
4.71
4.83
5.13
5.25
6.07
8.61
9.02
9.79
9.6
10.12
10.31
Tangible Book Value per Share
3.59
3.56
3.15
3.74
3.84
4.15
4.21
5
7.64
8.02
8.39
7.17
7.7
7.68
Basic Weighted Avg Shares
390
386
389
394
405
405
397
396
402
463
464
460
454
454
Sales/Revenue/Turnover
755
585
793
970
1,047
1,190
1,467
2,000
2,007
2,084
2,709
3,070
3,398
3,525
Operating Margin (%)
19.46
2.76
16.32
17.32
15.87
15.3
17.54
22.58
20.28
19.04
15.9
14.37
13
13.03
Depreciation Expense
34
41
50
77
90
92
91
96
92
116
147
205
224
- -
Net Income, GAAP
152
27
110
133
105
119
194
398
413
347
454
301
401
337
Effective Tax Rate (%)
14.39
26.65
13.47
14.1
13.65
12.91
13.9
13.98
11.11
9.68
9.84
10.44
7.7
4.22
Profit Margin (%)
20.13
4.61
13.91
13.69
10.02
10
13.25
19.91
20.57
16.63
16.74
9.8
11.79
9.56
Working Capital
861
719
405
655
661
696
486
728
1,938
1,784
1,921
1,398
1,485
1,213
LT Debt
- -
- -
- -
15
9
- -
55
154
101
192
322
519
371
238
Total Equity
1,720
1,730
1,769
2,105
2,176
2,324
2,357
2,737
4,324
4,501
4,984
5,007
5,185
5,304
Return on Invested Capital (%)
7.7
0.87
6
6.12
5.07
5.5
8.13
14.21
10.83
7.36
9.34
5.58
6.93
5.77
Return on Capital (%)
9.08
1.53
5.6
5.68
3.98
4.27
6.5
11.88
9.82
6.61
7.36
4.88
6.12
4.67
Return on Common Equity (%)
9.82
1.67
6.84
7.56
5.44
5.91
9.26
17.4
12.72
8.4
10.32
6.66
8.73
7.21

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
1,163
1,268
1,382
LT Borrowings
360
345
232
LT Finance Leases
4
4
7
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
465
465
465
Market Capitalization
8,101
6,706
7,789

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
3,535
3,432
3,552
Cash, Cash Equivalents & STI
1,681
1,553
1,489
Accounts Receivable, Net
1,101
1,165
1,213
Inventories
522
495
522
Total Current Liabilities
1,958
2,124
2,338
Payables & Accruals
- -
- -
- -
ST Debt
1,163
1,268
1,382
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.35%
15.36%
3.55%
Free Cash Flow
704.43%
176.03%
-77.93%
Net Income, GAAP
19.9%
3.59%
33.18%
Sales/Revenue/Turnover
16.18%
11.64%
10.7%
Total Cash Common Dividend
17.38%
11.55%
-22.38%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
685
566
648
1,323
3,070
2025
822
886
- -
854
3,398
2026
826
894
950
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.2
0.16
0.19
0.12
0.65
2025
0.25
0.31
- -
0.08
0.88
2026
0.24
0.21
0.21
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.42
0.01
0.02
0.47
2025
0.02
0.32
- -
0.02
0.37
2026
0.02
0.42
0.02
- -
- -

Company Description

CEO
Lei Xu
Full Time Employees
2,803
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 1, Dongjiu Road Tianjin TI China 300308
IPO Date
Sep 3, 2010
Website
ringpu.com
Business
Tianjin Ringpu Bio-Technology Co.,Ltd. is a prominent entity in the biotechnology and animal health sector, dedicated to the research, development, manufacturing, and distribution of a comprehensive array of veterinary biological products and pharmaceuticals within China and internationally. The company provides an extensive portfolio of vaccines and medications for various animal categories, including poultry, swine, aquatic life, cattle, sheep, and companion animals. Its offerings for pets encompass rabies inactivated vaccines, recombinant canine-a interferon, anesthetic agents like isoflurane and sevoflurane, and specialized treatments for bacterial diseases and heart conditions. For waterfowl, products include vaccines for duck tempusu and duck infectious serositis, along with refined egg yolk antibodies for gosling plague and duck viral hepatitis. Beyond specific animal applications, Tianjin Ringpu also supplies functional additives, such as natural plant extracts, immune polysaccharides, probiotics like Clostridium butyricum and Lactobacillus plantarum, enzyme preparations, and acidulants. The company further extends its reach with disinfection and cleaning solutions, as well as active pharmaceutical ingredients (APIs) like tilmicosin and florfenicol. Engaging in agricultural biotechnology, the firm also develops microbial agents, bio-fertilizers, and plant growth promoters to enhance farming productivity. With a strong commitment to innovation, Tianjin Ringpu allocates a significant portion of its revenue to research and development, which has led to breakthroughs like receiving clinical trial approval for China's first mRNA vaccine for economic animals in July 2025. Operating with a robust distribution network, the company serves livestock farmers, veterinary clinics, and pharmaceutical distributors across multiple countries. Established in 1998 and headquartered in Tianjin, China, the company is listed on the Shenzhen Stock Exchange.